Abstract Context Botulinum toxin A (BoNTA) has received regulatory approval for use in
neurogenic detrusor overactivity (NDO) and overactive bladder (OAB), but it remains …

The purpose of the study was to determine the efficacy and safety of nonantimuscarinic
treatments for overactive bladder. Medline, Cochrane, and other databases (inception to …

The standard treatment for overactive bladder starts with patient education and behavior
therapies, followed by antimuscarinic agents. For patients with urgency urinary incontinence …

Objective To evaluate safety and effectiveness of low-dose (100 U) onabotulinumtoxinA
(onabotA) bladder injections as an office procedure with topical anesthesia only for patients …

Botulinum toxin subtype A (BoNT-A) is a potent neurotoxin that can selectively modulate
neurotransmitter release from nerve endings, resulting in muscular paralysis. BoNT-A might …

Aim We carried out a systematic review and meta‐analysis to assess the efficacy and safety
of the drug for treating idiopathic OAB. Methods A literature review was performed to identify …

Following use of botulinum toxin in the 1980s for the treatment of detrusor sphincter
dyssynergia in patients with spinal cord injury (SCI), the potential therapeutic value of this …

Neurogenic detrusor overactivity (NDO) can result in lower and upper urinary tract
complications and eventually even in end-stage kidney failure. Since the driving force of this …

Purpose This study assessed the efficacy and safety of onabotulinumtoxinA according to
injection site for treatment of overactive bladder. Methods A systematic literature review …

Aims To investigate the frequency of phenotype profiling of patients with idiopathic
overactive bladder (OAB) syndrome, and to determine the effectiveness of treatment among …